Category: Press Release - Page 76 - Psychedelic Alpha

Read more about the article FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder

FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder

Post published:January 25, 2022
Post category:Press Release

Read more about the article Mydecine Partners with Combat Stress to Treat Post-Traumatic Stress Disorder in Veterans

Mydecine Partners with Combat Stress to Treat Post-Traumatic Stress Disorder in Veterans

Post published:January 24, 2022
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy as Part of its Psychedelic Drug DMT Intellectual Property

Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy as Part of its Psychedelic Drug DMT Intellectual Property

Post published:January 24, 2022
Post category:Press Release

Read more about the article Beckley Psytech Announces First Cohort of Psychotherapists Have Begun Training for Treatment Resistant Depression Phase 2 Trials

Beckley Psytech Announces First Cohort of Psychotherapists Have Begun Training for Treatment Resistant Depression Phase 2 Trials

Post published:January 24, 2022
Post category:Press Release

Numinus Wellness Inc. Reports Q1 2022 Results

Post published:January 20, 2022
Post category:Press Release

Read more about the article PharmaDrug Engages Octagon Media and Affiliated Wall Street Reporter for Investor Marketing Campaign

PharmaDrug Engages Octagon Media and Affiliated Wall Street Reporter for Investor Marketing Campaign

Post published:January 20, 2022
Post category:Press Release

Read more about the article BetterLife Receives FDA Response On Its Pre-IND Application For Major Depressive Disorder (MDD) Treatment With BETR-001

BetterLife Receives FDA Response On Its Pre-IND Application For Major Depressive Disorder (MDD) Treatment With BETR-001

Post published:January 20, 2022
Post category:Press Release

Read more about the article Psychedelic Science Leader Eleusis to Become Public Company in Merger with Silver Spike Acquisition Corp. II

Psychedelic Science Leader Eleusis to Become Public Company in Merger with Silver Spike Acquisition Corp. II

Post published:January 20, 2022
Post category:Press Release

Read more about the article Awakn Life Sciences Signs MOU with Maps

Awakn Life Sciences Signs MOU with Maps

Post published:January 19, 2022
Post category:Press Release

Numinus Announces Key Milestones in MAPS-Sponsored MDMA-Assisted Therapy for PTSD Clinical Trial

Post published:January 19, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.